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ABSTRACT: Aberrant proteins encoded from genes altered
in tumors drive cancer development and may also be
therapeutic targets. Here we derived a comprehensive
gene-alteration profile of lung cancer cell lines. We tested
17 genes in a panel of 88 lung cancer cell lines and found
the rates of alteration to be higher than previously thought.
Nearly all cells feature inactivation at TP53 and CDKN2A
or RB1, whereas BRAF, MET, ERBB2, and NRAS
alterations were infrequent. A preferential accumulation
of alterations among histopathological types and a mutually
exclusive occurrence of alterations of CDKN2A and RB1
as well as of KRAS, epidermal growth factor receptor
(EGFR), NRAS, and ERBB2 were seen. Moreover, in non-
small-cell lung cancer (NSCLC), concomitant activation of
signal transduction pathways known to converge in
mammalian target of rapamycin (mTOR) was common.
Cells with single activation of ERBB2, PTEN, or MET
signaling showed greater sensitivity to cell-growth inhibi-
tion induced by erlotinib, LY294002, and PHA665752,
respectively, than did cells featuring simultaneous activa-
tion of these pathways, underlining the need for combined
therapeutic strategies in targeted cancer treatments. In
conclusion, our gene-alteration landscape of lung cancer
cell lines provides insights into how gene alterations
accumulate and biological pathways interact in cancer.
Hum Mutat 30, 1199–1206, 2009. & 2009 Wiley-Liss, Inc.
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Introduction
Characterization of accumulated genetic alterations in cancer
cells is important not only to understand tumor biology, but also
to guide drug design and select patients who might benefit from a
given targeted cancer therapy. The promise of using proteins
encoded by mutated cancer genes, mainly kinases encoded by
oncogenes, as molecular targets for the development of novel
therapies, drives endeavors to identify novel mutated cancer genes
and to create catalogues of somatic mutations in cancer [Wang
et al., 2004; Sjoblom et al., 2006; Greenman et al., 2007; Thomas
et al., 2007]. The paradigm of the latter is the Catalogue of
Somatic Mutations in Cancer (COSMIC) database of the Well-
come Trust Sanger Institute (www.sanger.ac.uk/cosmic) [Forbes
et al., 2006], which brings together data on the mutation status of
hundreds of cancer-related genes in primary tumors and cancer
cell lines from a wide variety of tumor types.
In the particular case of lung cancer, several gene alterations are
known to contribute to its development, including activating
mutations and gene amplification at the oncogenes BRAF (MIM]
164757), epidermal growth factor receptor (EGFR) (MIM]
131550), ERBB2 (MIM] 164870), KRAS (MIM] 190070), NRAS
(MIM] 164790), PIK3CA (MIM] 1171834),MYC (MIM] 190080),
MYCL1 (MIM] 164850), and MYCN (MIM] 164840), as well as
inactivating intragenic mutations, homozygous deletions, and
promoter hypermethylation at the tumor suppressor genes BRG1/
SMARCA4 (MIM] 603254), LKB1/STK11 (MIM] 602216),
PTEN (MIM] 601728), CDKN2A (MIM] 600160),
RB1 (MIM] 180200), and TP53 (MIM] 191170) [Sanchez-
Cespedes 2007; Medina et al., 2008]. Some of these gene alterations
are known to be specific to lung tumor histologies [Westra et al.,
1993; Otterson et al., 1994; Kelley et al., 1995; Sanchez-Cespedes,
2007; Medina et al., 2008]. In addition, it is also well established
that some gene alterations are mutually exclusive, as is the case for
pairs of genes, such as KRAS and EGFR, or CDKN2A and RB1
[Otterson et al., 1994; Lynch et al., 2004; Paez et al., 2004], that
encode proteins acting in the same signaling pathway. However, a
profile of alterations at multiple well-known cancer genes in a large
panel of lung cancers has never been reported. This limits our
understanding of how gene alterations are distributed among lung
tumors and how they interact with one another.
Here, we attempt to delineate the gene-alteration profile of lung
cancer cell lines by screening for alterations of seventeen well-
known cancer genes, including point mutations at AKT1 (MIM]
164730) and EML4-ALK (MIM] 607442 for EML4 and MIM]
105590 for ALK) fusions, a small inversion within chromosome 2p
recently reported in a small subset of non-small-cell lung cancers
(NSCLCs) [Carpten et al., 2007; Soda et al., 2007]. We examined
the association between the genetic alteration profile and the
response to specific small molecule inhibitors.
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Material and Methods
Cell Lines
Cells were maintained in culture flasks in either DMEM (A549,
NCI-H1299, NCI-H23, Calu-3, NCI-H522, and EBC1) or RPMI
1640 (NCI-H446, NCI-H1650, NCI-H460, and NCI-N417)
(Invitrogen, Carlsbad, CA) supplemented with 10% (v/v) fetal
bovine serum, 2mM L-glutamine, 50mg/ml penicillin/strepto-
mycin, and 2.5 mg/ml fungizone. Cultures were kept at 371C in a
humidified atmosphere of 5% CO2/95% air. DNA, RNA, and
protein were extracted using standard protocols.
Screening for Gene Mutations and Deletions
Screening for mutations in AKT1 (exon 3), BRAF (exons 11 and
15),MET (MIM] 164860) (exons 16–20), ERBB2 (exon 20), EGFR
(exons 18–21), NRAS (codons 12, 13, and 61), PIK3CA (exons 1,
9, and 20), PTEN (exons 2–9), and CDKN2A (exons 1–3) was
performed by directly sequencing PCR products using primers
and conditions that have been previously described [Matsumoto
et al., 2007; Angulo et al., 2008; Medina et al., 2008], or that are
available upon request. Nucleotide numbering reflects cDNA
numbering with 11 corresponding to the A of the ATG transition
initiation codon in the reference sequence. We considered the
presence of homozygous deletions when there was a reproducible
absence of PCR product of one or more consecutive exons. The
mutational status of STK11, SMARCA4, KRAS, and TP53 was
either determined for those cases with incomplete/conflicting
information or gathered from previous publications [Harbors
et al., 1988; Yokota et al., 1988; Otterson et al., 1994; Shimizu
et al., 1994; Matsumoto et al., 2007; Angulo et al., 2008] (Supp.
Table S1) or from the Wellcome Trust Sanger Institute’s Cancer
Cell Line Project website (www.sanger.ac.uk/cosmic). In those
cases where mutation/deletion data were not available, cells with a
reported absence of RB protein expression were classified as RB1-
mutant. The presence of the EML4-ALK fusion gene was tested
according to previously published conditions [Soda et al., 2007].
Promoter Hypermethylation
The determination of promoter hypermethylation at CDKN2A
was evaluated by bisulfite treatment of the genomic DNA and
subsequent methylation-specific PCR, using previously published
protocols [Esteller et al., 2001].
Real-Time Quantitative Genomic PCR for Determining
Gene Amplification
To determineMET, ERBB2,MYC,MYCL, andMYCN amplification
we used quantitative real-time genomic PCR. The conditions and
primers used for MYC, MYCN and MYCL have been previously
described [Medina et al., 2008]. ERBB2 and MET primers and PCR
conditions are available upon request. The copy number of genomic
DNAwas measured by SYBR green using an ABI Prism 7900 Sequence
Detector (Applied Biosystems, Foster City, CA).
Inhibitors and Viability Assay
Rapamycin (mammalian target of rapamycin [mTOR] inhibi-
tor) and LY-294002 (PI3K inhibitor) were obtained from
Calbiochem (La Jolla, CA) and PHA665752 (MET inhibitor)
from Tocris Bioscience (Ellisville, MI). Erlotinib (N-(3-ethynyl-
phenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine) (EGFR in-
hibitor) was a gift from Roche Pharmaceuticals (Mannheim,
Germany). Erlotinib tablets were ground to powder and dissolved
in pure dimethyl sulfoxide (DMSO) to the desired concentration.
For the cell-survival assays, cells were seeded at a density of 5,000
cells/well (15,000 cells/well for N417) on 96-well plates. They were
allowed to recover for 12 hr before adding the drugs. Cells were
exposed to various concentrations of each drug for 48 or 72 hr,
and then the viable cell number was measured by the 3-(4,5-
dimethylthiazol-2)-2,5-diphenyltetrazolium bromide (MTT) as-
say. Briefly, 10 ml of a solution of 5 mg/ml MTT (Sigma Chemical,
Zwijndrecht, The Netherlands) was added to each well. After
incubation for 3 hr at 371C, the medium was discarded, the
formed formazan crystals were dissolved in 100 ml DMSO and
absorbance was determined at 596 nm by means of a microplate
reader (Bio-Rad, Hercules, CA). Viabilities were expressed as a
percentage of the untreated controls. The 50% growth inhibition
(IC50) was determined from the dose-response curve. Results are
presented as the median of at least two independent experiments
performed in triplicate for each cell line and each compound.
Antibodies and Western Blot Analysis
Anti-phospho-AKT (S473), anti-AKT, anti-S6, anti-phospho-S6
(S235/236), anti-phospho-MET (Y1234/Y1235), and anti-MET
were obtained from Cell Signaling Technology (Beverly, MA). For
western blotting, cells were seeded in 12-well culture plates and,
after incubating for 24 hr with the designated drug, were scraped
from the dishes into lysis buffer. Forty micrograms (mg) of total
protein were separated by SDS-PAGE, transferred to a PVDF
membrane, and blotted with the appropriate antibody according to
the manufacturer’s instructions.
Results
Gene Alteration Profiles of a Lung Cancer Cell Line Panel
To accurately determine the frequency of point mutations and
homozygous/intragenic deletions of known cancer genes in lung
cancer, avoiding the masking effect of the admixture with
nonmalignant cells, we chose to screen cancer cell lines, including
small-cell lung cancer (SCLC), squamous cell carcinomas (SCC),
adenocarcinomas (AC), large-cell carcinomas (LCC), and carci-
noids. Eighty-eight lung cancer cell lines were tested for alterations
at 17 genes: AKT1, BRAF, MET, EGFR, ERBB2, KRAS, STK11,
MYC, MYCL, MYCN, NRAS, PIK3CA, PTEN, CDKN2A, RB1, and
TP53, as well as the EML4-ALK fusion. Alterations were present in
all genes except AKT1. The EML4-ALK fusion was never detected.
A total of 98% (86/88) of the cell lines had alterations of at least at
one of the genes tested (Supp. Table S1 and Supp. Fig. S1). As
expected, alterations in tumor-suppressor genes were homozygous
whereas they were often heterozygous in oncogenes. Although two
different heterozygous TP53 mutations were detected in three cell
lines, these mutations are likely to have occurred in each of both
alleles resulting in the complete and biallelic inactivation of the
TP53 gene. The frequency of alterations when considering all
histological types, from the highest to the lowest, were ranked as
follows: TP53 (79%), CDKN2A (59%), RB1 (35%), STK11 (27%),
MYC-family (20%), KRAS (17%), PTEN (11%), PIK3CA (8%),
EGFR (7%), NRAS (6%), MET (5%), BRAF (2%), and ERBB2
(2%). The present study does not extend to mutation analysis at
another key tumor-suppressor gene, SMARCA4, which has
recently been found to be frequently altered in NSCLC [Medina
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et al., 2008]. Data on the mutation status of SMARCA4 for some
cell lines is also provided in Supp. Table S1.
To determine possible cell culture artifacts we compared the
mutational profile of lung cancer cell lines and lung primary tumors.
The mutational status of the TP53, STK11, KRAS, PIK3CA, EGFR,
and BRAF genes was available for non-small-cell lung primary
tumors [Angulo et al., 2008]. The ranking of the most commonly
mutated genes in lung primary tumors (TP534KRAS4ST-
K114EGFR4PIK3CA4BRAF) was very similar to that in cell
lines. However, the frequency of mutations at any gene in primary
tumors was about half that in lung cancer cell lines (Supp. Fig. S2),
suggesting a reduced effectiveness in the detection of gene alterations
in primary tumors, probably due to contamination by normal cells.
Alternatively, it is also possible that primary tumors are more
heterogeneous than cell lines with respect to the accumulated genetic
alterations. Since there are models for stepwise accumulation of
genetic alterations both for lung AC and SCC, we can not
completely discard that these differences arise as a consequence of
different progression stages between the tumors and cell lines
analyzed.
Gene Alterations and Histopathological Correlations
The distribution of gene alterations among patient character-
istics and tumor histopathologies are summarized in Table 1. As
previously described, alterations in CDKN2A and STK11 were
preferentially found in NSCLC, whereas alterations in PTEN, RB1,
and in the MYC family of genes, especially MYCL and MYCN,
were more common in SCLC. It is also interesting to note that
mutations at other components of the EGFR/KRAS signal
transduction pathway, i.e., EGFR, ERBB2, BRAF, and NRAS,
predominate in lung AC. The differences did not reach statistical
significance probably due to the few number of cell lines with
mutations at those genes. However, when combined together,
mutations at any of the different components of the KRAS pathway
(EGFR, ERBB2, KRAS, NRAS, and BRAF) were significantly more
frequent in lung AC as compared to SCCs (Po0.05; Fisher’s exact
test) and in NSCLC as compared to SCLC (Po0.00005; Fisher’s
exact test). Alterations at TP53 were present in a similar frequency
in both SCLC and NSCLC, indicating that its inactivation is
required for the development of all histopathological types of lung
cancer. Although very low frequency, mutations at PIK3CA were
also found in NSCLC and SCLC. The mutations found in the later
correspond to novel variants that need verification.
As previously reported, mutations at KRAS and EGFR
predominate in tumors from Caucasian and Asian patients,
respectively. However, a new observation that arises from our
study is the accumulation of alterations at theMYC-family of gene
in tumors from patients of Caucasian origin (Po0.05; Fisher’s
exact test). No associations were detected between alterations at
any gene and gender, or age, nor were gene alterations seen to have
accumulated in tumors of older patients. Rather than a definitive
observation, the lack of association between the presence of
mutations at EGFR and KRAS with tumors from nonsmokers and
smokers, respectively, is likely due to the lack of information on
the smoking habit of many the individuals.
Identification of Novel Variants
In addition to well-known somatic mutations with an
oncogenic effect within the helical and kinase domains of PIK3CA
[Samuels et al., 2004; Gymnopoulos et al., 2007; Angulo et al.,
2008], we identified two novel variants, both located near well-
characterized mutation hotspots. One of these is an insertion of
387 nt after the termination codon TGA that results in the
duplication of amino acids 1,051 to 1,068 (Fig. 1B) and the other
is a p.D1029Y substitution. Since no matched normal DNA was
available for these cell lines, we could not test whether these
mutations are germline polymorphisms or tumor-specific muta-
tions. Four cell lines carried MET alterations, including gene
amplification and two novel variants, p.L1158F (in the HCC15
cells) and p.T1259K (in the H1963 cells) (Fig. 1B and C). Again,
due to the lack of normal matched DNA for these cell lines we
could not verify the somatic nature of the amino acid
substitutions. However, the absence of constitutive METactivation
indicated by the lack of pMETY1234/Y1235 in these cell lines strongly
argues against an oncogenic role for the variants (Fig. 1D). The
H441, Calu3, HCC366, and HCC78 cells that were reported to
have high levels of pMETY1234/Y1235 [Rikova et al., 2007] did not
feature gene amplification or point mutations within the hotspots
tested here.
Cooperation of Several Biological Pathways in Lung
Carcinogenesis
It is widely accepted that alterations of genes in the same
biological pathways are not redundant in cancer cells. Accordingly,
genes that are altered in a mutually exclusive manner are likely to
encode proteins that act in the same biological pathway. This
hypothesis has been extensively borne out in lung cancer cells by
the lack of concomitant alterations at RB1 and CDKN2A, and at
EGFR and KRAS. Our data also confirm the mutually exclusive
nature of these pairs of alterations (Fig. 1A). Likewise, alterations
at ERBB2 and NRAS did not occur in the same cell lines or in cells
carrying EGFR and KRAS mutations, consistent with their
participation in the same signal transduction pathway. PTEN
and PIK3CA, which are both encoding proteins that modulate the
intracellular levels of the phosphoinositide-3,4,5-trisphosphate
(PIP3), were also found to be mutated in a mutually exclusive
manner. Only one cell line, Lu134, with a homozygous deletion at
PTEN, had a concomitant change at PIK3CA. The PIK3CA variant
is a p.D1029Y substitution, which has not been described before
and for which there is no evidence of its somatic nature. On the
other hand, there were concomitant BRAF- and NRAS-activating
mutations in the H2087 lung adenocarcinoma cells. The somatic
nature of the p.L597V mutation in BRAF was confirmed after
sequencing the DNA of the corresponding lymphoblastoid line
(BL-H2087). On the other hand, simultaneous mutations in signal
transduction pathways that are known to converge in the
modulation of mTOR activity, such as MET, PIK3CA/PTEN,
STK11, and KRAS/EGFR/NRAS/ERBB2, were present in some cell
lines, implying cooperation in cancer development. Namely, 17
(28%) of the 61 NSCLC cell lines carried single mutations,
whereas 16 (26%) and two (3%) of them carried double and triple
mutations, respectively, in any of this group of genes.
Correlation of Acquired Genetic Alterations With
Sensitivity to Small Molecule Inhibitors
To understand a possible effect of these genetic alterations on
the primary resistance to tyrosine kinase inhibitors (TKIs) and
other small molecule inhibitors, we selected a panel of 10 lung
cancer cell lines with a known genetic background for KRAS,
STK11, EGFR, PTEN, PIK3CA, andMET, and tested the sensitivity
to treatment with inhibitors of PI3K (LY294002), mTOR
(rapamycin), MET (PHA665752), and EGFR (erlotinib). As
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subrogate markers to test the ability of the drug to inhibit its
target molecule we measured the levels of pAKTSer473 (for PI3K
and EGFR inhibitors), pS6Ser235/236 (for mTOR inhibitor), and
pMETY1234/Y1235 (for MET inhibitor). The calculated IC50 for the
different compounds is summarized in Figure 2A. A marked
genotype–drug sensitivity association was observed for the Calu-3
and EBC-1 cells, which were highly responsive to growth
inhibition triggered by erlotinib and PHA665752 compounds,
respectively. The effectiveness of these treatments was also
measured by their ability to decrease phosphorylation at their
target molecules or at downstream effectors (Fig. 2B). We did not
observe a low IC50 in response to treatment with PHA665752, in
the H1963 or HCC15 cell lines (data not shown). These carry
amino acid substitutions at the tyrosine kinase domain of MET,
which is further indication that these variants are not functionally
significant. Similarly, the Calu-3 cells that carry high levels of MET
phosphorylation (Fig. 1D) but do not exhibit gene amplification
or mutations were insensitive to PHA665752. Interestingly, the
H522 cells evidenced a strong sensitivity to PHA665752. These
cells neither carry amplification/point mutations at MET nor
MET phosphorylation. Thus, the characterization of the gene
alterations underlying the sensitivity of these cells to MET
inhibitors will be of interest. Although the differences were not
as marked, we also noted that sensitivity to LY294002, as indicated
by the lower IC50, was increased in the H446 and N417 cell lines,
both of which are PTEN-deficient. Similarly, the lowest IC50 to
rapamycin was observed for the N417, H446, EBC-1, and Calu-3
cells (Fig. 2A and B). Some of these cells carry constitutive
activation of AKT due to the presence of PTEN inactivation (the
N417 and H446), or to ERBB2 gene amplification (Calu-3).
Intriguingly, the triple mutant KRAS-STK11-PIK3CA (H460) and
EGFR-PTEN (H1650) cells were extremely resistant to rapamycin,
LY294002, and erlotinib. Thus, we investigated the effect of the
combined treatment with erlotinib and LY294002 on cell growth,
and found that the addition of erlotinib significantly increased the
efficiency of cell-growth inhibition of the LY294002 compound in
H1650 cells, but not in H460 cells (Fig. 3A and B).
Discussion
We provide a detailed gene-alteration profile of lung cancer cells
of distinct histologies. In full compliance with Knudson’s two-hit
hypothesis [Knudson, 1971], mutations in tumor suppressors, but
not in oncogenes, were always homozygous. We also confirmed
the disproportionately high frequency of occurrence of some gene
alterations in specific histological types, which probably reflects
differences in the cell type of origin. The overall profile of genes
mutated in lung cancer was comparable between lung primary
tumors and lung cancer cell lines. However, the frequency of
mutations at any gene was higher in cell lines, which strongly
implies a masking effect due to the admixture of nonmalignant
cells that hinders the detection of point mutations and insertions/
deletions in the primary tumors. This obstacle has been noted
before [Sanchez-Cespedes, 2007; Thomas et al., 2006] and is a
significant problem that may be solved by the use of a novel
generation of sequencers [Thomas et al., 2006], or by other
technical approaches like careful microdissection of tumor cells.
TP53 was the most frequently altered gene in the lung cancer
cell lines. Nearly 80% of the cell lines carry alterations of this
tumor suppressor. Similarly, alterations at the cell cycle compo-
nents, either RB or CDKN2A, were also extremely common. The
high frequency of TP53 and CDKN2A/RB1 alterations in all
histopathologies is a demonstration of their important role in
lung cancer development. It is tempting to speculate that TP53
and CDKN2A/RB1 inactivation in lung cancer may be universal
and are thus a requisite for the evolution of lung tumors.
Figure 1. Gene alterations in lung cancer cell lines. A: Profile of genes altered in human lung cancer cell lines. The presence of alterations is
indicated by gray bars. Black squares indicate no data. The black lines in the PIK3CA oncogene refer to the two variants of unknown oncogenic
potential. The histopathology is also shown. B: PIK3CA and MET variants in the RERF-LC-OK and HCC15 cell lines. Nucleotide numbering reflects
cDNA numbering with 11 corresponding to the A of the ATG transition initiation codon in the reference sequence C: MET gene amplification in
lung cancer cell lines revealed by quantitative PCR. The relative MET copy number was determined by comparison with an unrelated
control locus, MDH2, on chromosome 7q11. Cells with MET amplification are indicated with an arrow. D: Western blot anti-phospho-MET
(pMETY1234/Y1235) and anti-MET (MET) in the indicated cell lines. Constitutive MET activation is present in the EBC-1 and Calu-3 cells, but not in
the HCC15 and H1963 cells, which carry gene variants of unknown biological significance.
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Conversely, alterations at some oncogenes, such as BRAF, ERBB2,
and MET, were infrequent.
It was remarkable the differences in the activation of
components of the KRAS pathway among the lung cancer
histopathologies. While alterations at any of the BRAF, EGFR,
ERBB2, KRAS, or NRAS was significantly more common in AC as
compared to SCC, virtually none of the SCLC carry alterations at
any of those genes. This strongly points out towards completely
different mechanisms of carcinogenesis for NSCLC and SCLC and
likely accounts for the distinct clinical behavior of both types of
lung cancer.
Although mutations outside the hotspots may increase the
frequency of alterations at these genes to some extent, it seems
certain that their contribution will be confined to a small subset of
lung tumors. However, given that the encoded proteins are targets
for small molecule inhibitors, the context in which these
mutations arise (e.g., histological type, concomitant mutations
at other genes) needs to be better understood. We confirmed the
lack of concomitant mutations in those genes encoding proteins
acting in the same biological pathway, such as CDKN2A/RB1,
KRAS/EGFR/ERBB2, and PIK3CA/PTEN. Apart from these,
simultaneous alterations were found in most of the other genes.
Intriguingly, we also found that BRAF-NRAS, were genetically
altered in the same cells, suggesting that the collaboration of the
encoded proteins affects the development of the cancer. Similarly,
it was previously reported that BRAF mutations involving codons
other than 600 or 601 were highly likely to co-occur with a RAS
family mutation [Thomas et al., 2007]. It is interesting to note the
frequent concomitant activation of signal transduction pathways
Figure 2. Genotype of the cell lines and sensitivity to specific inhibitors. A: The IC50 (mM) for each compound (RAPA, rapamycin; LY, LY294002, PHA,
PHA665752; and Erlo, erlotinib) is indicated within the boxes. Treatments were applied for 72 hr. B: Immunoblotting analysis depicting the decreased
phosphorylation of the indicated protein upon administering increasing concentrations of the compound. Treatments were applied for 24 hr.
Figure 3. Cell-growth inhibition upon administering combined
LY294002 and erlotinib treatment. Lines represent the cell survival
relative to untreated controls of the MTT assays in the H1650 and
H460 cells treated with increasing concentrations of LY294002, alone
or with 5mM erlotinib for 72 hr. Error bars indicate the standard
deviation of three replicates.
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that converge in the modulation of mTOR activity upon different
stimuli, such as KRAS/EGFR/ERBB2, PIK3CA/PTEN, and STK11
[Corradetti and Guan, 2006].
Selective small inhibitors against molecules that participate in
different signaling pathways have been approved or are at various
stages of development for clinical use in cancer patients. In this
new scenario of targeted therapies, the response to a given
therapeutic drug is likely to depend on the genetic background of
the tumor. Similarly to previous observations [McDermott et al.,
2007], our present results show how lung cancer cells with single
alterations at MET, PTEN, or ERBB2/EGFR are sensitive to MET
(PHA665752), PI3K (LY294002), and EGFR (erlotinib) inhibitors,
respectively. However, this does not hold true in cells with
activation of multiple signaling pathways, suggesting that there are
interconnections among pathways that enable cells to bypass the
negative effects on cell growth triggered by the small inhibitor. We
found that in the originally resistant EGFR/PTEN double-mutant
cells, erlotinib sensitized the cells to the effect of the LY294002
compound, which suggests that the use of drug combination
strategies could improve sensitivity to specific therapies. Current
efforts to understand the mechanisms of tumor resistance,
especially to TKIs in lung cancer, further support this hypothesis
[Rikova et al., 2007; Engelman et al., 2007]. Guo et al. [2008]
reported that in EGFR-mutant cells which are sensitive to EGFR
inhibitors, EGFR drives other receptors tyrosine kinases (RTKs)
and a network of downstream signaling that collapse with drug
treatment. In these cells, secondary drug resistance appears
through the generation of novel gene alterations at another
RTK, MET, preventing such collapse and thus bypassing the
inhibitory effect of the drug. Taken together these observations are
strong evidence that different signal transduction pathways
assemble in networks, through the use of some common
components. Beyond the contribution to the understanding of
cell biology, our observations draw attention to the need to stratify
tumors according to their genotype and histology and suggest that
the combination of pathway-selective therapies will eventually be
required for the treatment of many solid tumors.
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